Methods for the Estimation of the NICE Cost-Effectiveness Threshold (Claxton supply-side threshold)
This method estimates how much it costs the NHS to gain one additional quality-adjusted life-year (QALY) by analyzing how changes in overall NHS spending affect health outcomes like mortality and quality of life. It helps decide whether a new health technology is worth funding by comparing its cost per QALY to this threshold.
At a glance
Use when
Setting or evaluating cost-effectiveness thresholds for health technologies in publicly funded systems like the NHS; assessing opportunity costs of new interventions; informing reimbursement decisions where empirical thresholds are needed
Avoid when
When high-quality contemporaneous data are unavailable; in private healthcare systems with different funding dynamics; when evaluating very small-scale or localized interventions not impacting system-level budgets
Inputs
NHS programme budgeting data, disease-specific mortality rates, quality-of-life data, expenditure and outcome data across Primary Care Trusts
Outputs
Estimated cost-effectiveness threshold in £/QALY, uncertainty analysis (probabilities for thresholds < £20,000 and < £30,000), adjusted thresholds under financial pressure
How it works
The method uses econometric analysis of NHS programme budgeting data to estimate the relationship between changes in total expenditure and disease-specific mortality. It extends this to life-years and QALYs by incorporating quality-of-life adjustments. A central cost-effectiveness threshold of £12,936 per QALY (2008 prices) is derived, with uncertainty and structural analysis suggesting it may be an overestimate, particularly for high-cost technologies. The threshold varies under financial pressure, supporting a lower threshold for cost-increasing technologies.
- HTA domains
- Costs & Economic Evaluation
- Categories
- Cost-effectiveness Modelling
- Assumptions
- Changes in NHS expenditure lead to measurable changes in health outcomes; the relationship between spending and mortality is estimable across programme budget categories; quality-of-life impacts can be modeled alongside life-years gained
- Strengths
- Based on real NHS data; provides empirical basis for threshold setting; incorporates uncertainty and structural considerations; accounts for financial pressure and disinvestment effects
- Limitations
- Substantial uncertainty due to data limitations; central estimate may be an overestimate; generalizability across time and settings may be limited; relies on historical data (2008–10)
- Also known as
- Claxton supply-side threshold, NICE cost-effectiveness threshold estimation method
Questions this answers
- › What is the estimated cost per QALY gained based on NHS opportunity costs?
- › How does NHS spending relate to changes in mortality and health outcomes?
- › How can the cost-effectiveness threshold be empirically estimated using real-world budget and outcome data?
- › How does financial pressure on the NHS affect the appropriate cost-effectiveness threshold?
- › Should the threshold differ for technologies that increase versus reduce NHS costs?
References & sources
Similar by meaning
- Irish Cost-Effectiveness Threshold (45,000/20,000 EUR per QALY)
- Modifying NICE's Approach to Equity Weighting
- Cost-Effective but Unaffordable Paradox / Nonmarginal Health Opportunity Cost Method
- Hungarian relative-QALY-gain stratified cost-effectiveness threshold framework (1.5-3x GDP)
- Generalized Risk-Adjusted Cost-Effectiveness (GRACE)
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.